Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BIND Begins New Cancer Trial

By Drug Discovery Trends Editor | January 7, 2011

BIND Biosciences announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients.  BIND-014, the first product candidate to enter clinical evaluation from BIND’s broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.  Docetaxel is the active ingredient in Taxotere, which is approved in major cancer indications, including breast, prostate and lung. In preclinical cancer models, BIND-014 was shown to deliver up to 20 times more docetaxel to the tumor site than an equivalent dose of Taxotere.  The increased accumulation of docetaxel at the site of disease in preclinical systems translated to marked improvements in antitumor activity and tolerability. 

“Initiating clinical development of BIND-014, our most advanced product candidate, is an important milestone for BIND.  Preclinical studies demonstrate the ability of BIND’s targeted nanoparticle technology to enhance the trafficking of cytotoxic agents to cancer cells and increase efficacy, which, if confirmed in human trials, has the potential to improve outcomes for patients,” said Scott Minick, President and Chief Executive Officer of BIND Biosciences. “By precisely targeting and controlling the exposure of drugs to disease sites, BIND’s Medicinal Nanoengineering platform has the potential to produce drug candidates across an array of therapeutic areas including oncology, inflammatory disease and cardiovascular disorders.”

The Phase 1 study has an ascending, intravenous dose design to assess the safety, tolerability and pharmacokinetics of BIND-014 in approximately 30 cancer patients. The primary objective of the study is to determine the maximum tolerated dose of BIND-014 and to assess preliminary evidence of antitumor activity.  Patients are currently being screened for eligibility in this clinical trial, which is being conducted at the Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Arizona in collaboration with the Translational Genomics Research Institute (TGen) and the Scottsdale Healthcare Research Institute.

“The preclinical profile of BIND-014 demonstrating activity against many types of very common cancers is very encouraging,” commented Daniel D. Von Hoff, M.D., F.A.C.P., Principal Investigator for the study and Physician in Chief and Distinguished Professor at TGen and Chief Scientific Officer for US Oncology and the Scottsdale Clinical Research Institute. “My colleagues and I are excited to work with BIND in the clinical development of BIND-014 for the benefit of our patients.”

Date: January 7, 2010
Source: BIND Biosciences www.bindbio.com


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE